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1. Introduction 
Radiologic procedures such as coronary angiography utilizing intravascular contrast media 
(CM) injections are being widely applied for diagnostic and therapeutic purposes. These led 
to a parallel increase in the incidence of contrast-induced nephropathy (CIN). Renal failure 
requiring dialysis after contrast media administration is associated with a 40% in-hospital 
mortality rate and has a 2-year mortality rate of 80%. Approximately $180 million are spent 
annually to manage CIN in the US. The large number of patients who are severely affected 
by CIN underscores the importance of addressing known risk factors and preventions for 
CIN. Patients at risk for CIN can often be identified with a routine medical history, physical 
examination and laboratory analysis before the procedure. Two of the major risk factors of 
CIN are pre-existing renal failure and diabetes mellitus. After the high-risk patient 
population has been identified and risk factors addressed, the next step in preventing CIN is 
the use of different prophylactic therapies. The following chapter provides an overview of 
current risk factors and preventive methods of CIN. 
2. Definition, differential diagnosis and incidence of CIN 
The most commonly used definition for CIN in clinical trial is the elevation of serum 
creatinine by ≥0.5mg/dl or ≥25% occurring within 48 hours after administration of CM, and 
the absence of an alternative etiology. Serum creatinine is the standard marker to detect 
CIN. However, serum creatinine demonstrates major limitations. Using the Cockcroft-Gault 
and the Modification of Diet in Renal Disease equations are useful in estimation of the GFR. 
Serum cystatin C has been proposed as an alternative endogenous marker of GFR showing 
higher correlation to standard clearance methods such as inulin or iohexol clearance. Serum 
cystatin C may detect CIN one to two days earlier than creatinine. Also, recent studies 
documented that serum and urine neutrophil gelatinase-associated lipocalin is an early 
predictive biomarker of CIN in patients underwent coronary angiography (Shaker et al., 
2010). Cholesterol atheroemboli, volume depletion, and interstitial nephritis should consider 
in differential diagnosis of CIN. Before coronary angiography, the volume status of high-
risk patients can be assessed through the inferior vena cava index or bioimpedance 
spectroscopy. The incidence of CIN is reported to be 0.6-2.3% in general population who do 
not have any risk factor for CIN, but the incidence can be increased to 90% in patients at 
high risk for CIN (Toprak, 2007). 
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2.1 Pathophysiology of CIN 
The pathogenesis of CIN is unclear. The proposed mechanisms are medullary hypoxia due 
to decreased renal blood flow secondary to renal artery vasoconstriction, tubular obstruction 
and direct tubular toxicity of the CM due to apoptosis and oxidative damage. Endothelial 
dysfunction and renal microcirculatory alterations also may play a role. The development of 
CIN is affected by changes in renal hemodynamics, such as increased activity of renal 
vasoconstrictors and decreased activity of renal vasodilators. Other factors that may 
decrease renal blood flow include increased viscosity of CM and increased erythrocyte 
aggregation induced by CM, which results in diminished oxygen delivery. Contrast agents 
have been found to reduce antioxidant enzyme activity, and direct cytotoxic effects 
mediated by oxygen free radicals. Apoptosis is also involved as a result of cellular injury. 
Hyperosmolar contrast agents induce renal hemodynamic changes caused by osmolar-
driven solute diuresis with activation of tubuloglomerular feedback or an increase in tubular 
hydrostatic pressures, which may cause compression of the intrarenal microcirculation and a 
decreased GFR. Also hyperosmolar contrast agents have direct toxic effects on renal 
epithelial cells. In addition, DNA fragmentation was increased in cells exposed to 
hyperosmolar CM.  
2.2 Clinical course and outcomes 
CIN may range in severity from asymptomatic, nonoliguric transient renal dysfunction to 
oliguric severe renal failure that necessitates permanent dialysis. CIN is reported to be the 
third leading cause of in-hospital acute renal failure after hypotension and surgery. 
Approximately $180 million is spent annually to manage CIN in the US. Dangas et al. 
showed that in-hospital outcomes such as death (6.3% vs 0.8%), cardiac death (4.0% vs 
0.5%), coronary artery bypass grafting (5.8% vs 0.5%), major adverse cardiac event (9.3% vs 
1.1%), packed red cell transfusion (28% vs 6%), vascular surgery of access site (5.6% vs 
2.6%), post-procedure length of stay (6.8±7.1 vs 2.3±2.5) were significantly higher in CIN 
developed patients compare with control (p<0.0001). In cumulative one-year outcome death, 
out-of-hospital death and major adverse cardiac events were significantly higher in CIN 
developed patients (p<0.0001) (Dangas et al., 2005). In a study of acute myocardial infarction 
patients undergoing primary angioplasty, it was found that CIN developed patients have 
significantly higher incidence of high-rate atrial fibrillation (p=0.01), high-degree conduction 
disturbances requiring permanent pacemaker (p=0.04), acute pulmonary edema (p=0.008), 
respiratory failure requiring mechanical ventilation (p<0.0001), cardiogenic shock requiring 
intra-aortic balloon (p<0.0001), and acute renal failure requiring renal replacement therapy 
(p<0.0001) ( Marenzi et al., 2004).  
2.3 Risk factors for CIN 
Specific factors that increase the risks for development of CIN are related to the patient, the 
contrast media, and the procedure (Table 1).  
2.3.1 Patient-related risk factors 
Older age 
The possible reasons of the high incidence of CIN in elderly were age-related changes in 
renal function, more difficult vascular access following tortuosity, calcification of the vessels  
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Risk Factors Odds Ratio (95%CI) p Value 
Kidney Related Risk Factors   
Pre-existing renal failure   
  Preprocedural creatinine 2.0-2.9 mg/dl 7.37 (4.78-11.39) <0.0001 
  Preprocedural creatinine ≥ 3mg/d 12.82 (8.01-20.54) <0.0001 
Diabetes mellitus-Diabetic nephropathy   
  Preprocedural creatinine≤ 1.1mg/dl 1.86 (1.20-2.89) 0.005 
  Preprocedural creatinine 1.2-1.9 mg/dl 2.42 (1.54-3.79) <0.001 
Use of nephrotoxic drugs   
Low effective circulatory volume 1.19 (0.72-1.95) 0.05 
Cardiovascular System Related Risk Factors   
Class III-IV congestive heart failure 2.20 (1.60-2.90) <0.0001 
Left ventricle ejection fraction<40% 1.57 (1.14-2.16) 0.005 
Acute myocardial infarction ≤ 24 h 1.85 (1.31-2.63) 0.0006 
Hypertension 2.00 (1.40-2.80) 0.0001 
Periprocedural hypotension 2.50 (1.70-3.69) <0.00001 
Multi-vessel coronary involvement 3.24 (1.07-9.82) 0.038 
Peripheral vascular disease 1.90 (1.40-2.70) <0.0001 
Preprocedure shock 1.19 (0.72-1.96) 0.05 
Using intra-aortic balloon pump 15.51 (4.65-51.64) <0.0001 
Bypass graft intervention 4.94 (1.16-20.9) 0.03 
Time-to-reperfusion ≥6 h 2.51 (1.01-6.16) 0.04 
Pulmonary edema 2.56 (1.42-4.52)  0.001 
Demographic Risk Factors   
Age >75 years 5.28 (1.98-14.05) 0.0009 
Female gender 1.4 (1.25-1.60) 0.0001 
Contrast Media Related Risk Factors   
High total dose of contrast agent (>300 ml) 2.8 (1.17-6.68) 0.02 
Osmolality (Low- vs. high-osmolality) 0.50 (0.36-0.68)  
Short duration of two contrast administration 4.4 (2.9-6.5) <0.0001 
Other Possible Risk Factors   
Procedural success 0.27 (0.19-0.38) <0.0001 
Baseline hematocrit 0.95 (0.92-0.97) <0.00001 
Hyperuricemia 4.71 (1.29-17.21) 0.019 
ACE inhibitors 3.37 (1.14-9.94) 0.028 
Angiotensin Receptor Blockers 2.70 (1.25-5.81) 0.011 
Metabolic Syndrome 426 (1.19-15.25) 0.026 
Hypoalbuminemia 5.79 (1.71-19.64) 0.005 
  Hypercholesterolemia   
  Renal transplant   
  Multiple myeloma   
  Diuretics   
  Intra-arterial contrast administration   
  Sepsis, cirrhosis   
Table 1. Risk factors for the development of contrast-induced nephropathy 
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requiring greater amount of CM, defective prostaglandin synthesis, and the presence of 
renovascular disease. Furthermore, hypovolemia is very common in elderly patients. In a 
prospective study in which elderly patients (≥70 years) were subjected to cardiac 
catheterization, 11% developed CIN (Rich & Crecelius, 1990).  In another study, CIN 
incidence was 17% in elderly patients (>60 years) as compared with 4% in younger patients 
(Kohli et al., 2000). In 208 patients with acute myocardial infarction who underwent 
coronary intervention, it was found that an age of ≥75 years was an independent risk for 
CIN (OR=5.28, p=0.0009) (Marenzi et al., 2004). 
Gender 
In a retrospective study of 8628 patients who underwent PCI, female sex was an 
independent predictor of CIN (OR=1.4, p<0.0001). One-year outcome analyses by gender 
showed a higher mortality among females than among males in a cohort of CIN patients 
(14% vs 10%, p=0.05) (Iakovou et al., 2003). The findings of this study contradict those of a 
previous randomized controlled trial of ionic vs nonionic CM, in which a multivariate 
analysis identified male gender as an independent risk factor for CIN (Rudnick et al., 1995). 
Whether female gender is truly an independent predictor of CIN will require further 
confirmatory studies. 
Pre-existing renal disease 
The major risk factor for CIN is a GFR<60 ml/min/1.73 m2. Chronic kidney disease is 
associated with decreased vasodilatory response, which is important in developing CIN, 
and in patients with renal insufficiency, the clearance of CM is slower than in normal 
subjects. In a study of 7586 patients who underwent coronary intervention, CIN developed 
in 22.4% of the patients who had serum creatinine levels of 2.0 to 2.9 mg/dl and in 30.6% of 
those with serum creatinine levels of 3.0 mg/dl or higher, compared with 2.4% of patients 
with serum creatinine levels <1.1 mg/dl ( Rihal et al., 2002). Two other studies (Moore et al., 
1992; Barrett et al., 1992) reported that the incidence of CIN increased from 4% to 20% as the 
baseline serum creatinine increased from 1.2 to 2.9 mg/dl. In another study, the incidence of 
CIN increased from 8% to 92% as the serum creatinine increased from 1.5 to 6.8 mg/dl. 
Furthermore, the probability of CIN requiring dialysis increases from 0.04% to 48% as the 
baseline GFR decreases from 50 to 10 ml/min (McCullough et al., 1997). 
Diabetes mellitus 
Patients with diabetes constitute an important group at high risk of developing CIN. 
Patients with diabetic nephropathy and a mean serum creatinine of 6.8 mg/dl had a 92% 
incidence of CIN after coronary angiography (Weinrauch et al., 1977). Patients with diabetes 
who have advanced chronic renal failure because of causes other than diabetic nephropathy 
are at significantly higher risk of developing CIN like diabetic nephropathy. On the other 
hand, studies have shown that when pre-existing renal disease is present, patients with and 
without diabetes are similarly at risk of CIN, which correlates with the degree of renal 
disease. Some authors have suggested that DM in the absence of nephropathy, particularly 
in insulin-dependent patients with diabetes, is associated with an increased risk of CIN 
(McCullough et al., 1997; Toprak 2007). In a study, it was found that the incidence of CIN 
was rather low (2%) in patients with neither diabetes nor azotemia, significantly higher 
(16%) in individuals with diabetes but preserved renal function, and much higher (38%) in 
patients who had both diabetes and azotemia (Lautin et al., 1991). In another study, the 
incidence of CIN was found to be 2% in patients without diabetes and 3.7% in patients with 
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diabetes with a baseline creatinine of 1.1 mg/dl or less (OR=1.86, p=0.005). When renal 
function is mildly impaired (serum creatinine level 1.2 to 1.9 mg/dl), the risk of CIN in 
patients with diabetes mellitus increases to 4.5% (OR=2.42, p<0.001) ( Rihal et al., 2002).  
Other studies have failed to corroborate this connection (Parfrey et al., 1989). However, 
given that, those with diabetes alone were found to be at slightly higher risk of CIN than the 
general population. 
Pre-diabetes 
In a study of 421 patients who underwent coronary angiography with renal insufficiency, 
we presented that pre-DM increase the incidence of CIN 2.1-fold in comparison to patients 
with normal fasting glucose (NFG) but pre-DM is not as strong as DM as a risk of 
developing CIN. CIN occurred in 20% of the DM (RR=3.6, p=0.001), 11.4% of the pre-DM 
(RR 2.1, p=0.314) and 5.5% of the NFG group. The decrease of GFR was higher in DM and 
pre-DM (p=0.001 and p=0.002, respectively). Length of hospital stay was 2.45 ± 1.45 day in 
DM,  2.27 ± 0.68 day in pre-DM, and  1.97 ± 0.45 day in NFG (p<0.001, DM vs. NFG and 
p=0.032, pre-DM vs. NFG). The rate of major adverse cardiac events was 8.7% in DM, 5% in 
pre-DM, and 2.1% in NFG (P=0.042, DM vs. NFG). Hemodialysis was required in 3.6% of 
DM, and 0.7% in pre-DM (P=0.036, DM vs. NFG), and the total number of hemodialysis 
sessions during 3 months was higher in DM and pre-DM (P<0.001). Serum glucose ≥124 
mg/dl was the best cut-off point for prediction of CIN (Toprak et al., 2007). 
Congestive heart failure and reduced left ventricular ejection fraction 
Studies have shown that reduced left ventricular ejection fraction (LVEF) (≤49%) and 
advanced congestive heart failure are independent risk factors for CIN. In a study, Dangas 
et al. showed that LVEF below 40% is an independent predictor of CIN (Dangas et al., 2005). 
We have previously reported that if the LVEF is greater than 30%, this condition does not 
show any significant effect on the development of CIN (Toprak et al., 2003). In a study it was 
shown that congestive heart failure was an independent risk for CIN (OR=1.53, p=0.007) 
(Rihal et al., 2002). In a cohort study it was found that congestive heart failure is a risk for 
CIN in patients who underwent PCI (OR=2.2, p<0.0001) (Bartholomew et al., 2004). 
Hypertension 
Hypertension has been categorized as a risk factor for CIN in some research. In a study of 
8628 patients who underwent percutaneous interventions, hypertension was found to be an 
independent predictor of CIN (OR=1.2, p=0.0035) (Iakovou et al., 2003). In another cohort 
study, hypertension was a risk for CIN in patients who underwent PCI (OR=2.0, p=0.0001) 
(Bartholomew  et al., 2004). 
ACE Inhibitors and angiotensin receptor blockers 
ACE inhibitors have been identified as a risk factor for CIN because of their potential to 
reduce renal function. On the other hand, some small studies have shown that the 
nephrotoxicity of CM may be reduced because of decreased renal vasoconstriction by 
inhibition of angiotensin II. In a randomized controlled study with 71 patients with diabetes 
who underwent coronary angiography randomized to captopril or control, 25-mg captopril 
was given three times daily. There was a significant decrease in CIN in the patients who 
received captopril compared with the control group (6% vs 29%, respectively, p<0.02) 
(Gupta et al., 1999). We have performed a randomized controlled study in 80 patients with 
serum creatinine below 2 mg/dl who underwent coronary angiography. Captopril was 
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administered in 48 patients before coronary angiography. Five patients (10.4%) in the 
captopril group developed CIN, compared with only one patient (3.1%) in the control group 
(p=0.02) (Toprak et al., 2003). In a study of 230 patients with renal insufficiency and age ≥65 
years we found that chronic ACE inhibitor administration was a risk for developing CIN. 
CIN occurred in 17 patients (15.6%) in the ACE inhibitor group and 7 patients (5.8%) in the 
control group (p=0.015). Chronic ACE inhibitor administration was a risk indicator of CIN 
(OR=3.37, p=0.028) (Cirit et al., 2006). In another study, 421 patients with renal insufficiency 
who underwent coronary angiography, use of ACE inhibitors or ARB was a risk for CIN in 
multivariate analysis (OR=2.7, p=0.011) (Toprak et al., 2007). In a recent study, the impact of 
renin-angiotensin and aldosterone system blockade on the frequency of CIN was assessed 
retrospectively. Patients treated with ACE inhibitors or ARB (n=269) and were not treated 
with them (n=143) underwent coronary angiography included to the study. CIN developed 
11.9% in ACE-inhibitor using group and 4.2% in control group (p=0.006). Use of ARB or 
ACE inhibitors was found as a risk for CIN (OR=3.08, p=0.016) (Kiski et al., 2010). Checking 
the use of ACE inhibitors or ARB before coronary angiography seems to be a useful guide in 
tracking risk assessment for CIN.  
Nephrotoxic drugs 
Sulfonamides, aminoglycosides, and their combination with furosemide are particularly 
potent. Cyclosporin A may intensify medullary hypoxia, and cisplatin can attach to 
sulfhydryl groups. Mannitol can increase the metabolic workload in the kidney, and 
amphotericin B can cause the effect of a combination of mannitol and cyclosporine A. 
However, the individual roles of these medications as independent risk factors of CIN have 
not been determined in large trials. Nonetheless, it seems quite likely that nonselective 
NSAIDs and selective COX-2 inhibitors decrease the vasodilatory prostaglandins in the 
kidney and potentiate the vasoconstrictive effect of CM. 
Multiple myeloma 
The pathomechanism of this process has been explained by the precipitation of CM molecules 
together with Tamm–Horsfall proteins and other abnormal proteins, tubular epithelial cells 
damaged and desquamated as a result of ischemia, direct contrast toxicity, or disturbed 
function of integrins. In studies conducted on animals, intratubular light chains, particularly in 
the setting of intravascular volume depletion, have been found to augment the nephrotoxic 
potential of CM (Holland et al., 1985).  Studies showed an incidence of CIN of only 0.6–1.25% 
in patients with myeloma if dehydration is avoided (McCarthy & Becker, 1992). 
Metformin 
The oral antidiabetic agent metformin is not itself nephrotoxic, but it is known that patients 
who are receiving metformin may develop lactic acidosis as a result of CIN. A decline in 
renal function after contrast exposure could adversely affect the clearance of metformin. The 
complication was almost always observed in diabetic patients with decreased renal function 
before injection of CM. It seems safer to instruct patients especially at high risk for CIN not 
to take this drug for 48 h or so after CM administration and resume taking the drug only if 
there are no signs of nephrotoxicity. 
Hypercholesterolemia 
In the literature, there are limited studies on the relationship between hypercholesterolemia 
and CIN. According to these studies, hypercholesterolemia aggravates CIN through the 
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reduced production of nitric oxide (Yang et al., 2004). Altered nitric oxide-dependent renal 
vasodilatation, which is important in the pathogenesis of CIN, is prevalent in 
hypercholesterolemia. 
Hyperuricemia 
It has been suggested that tubular obstruction by uric acid plays a role in the pathogenesis 
of CIN. In a prospective cohort study we evaluated 266 patients who undergoing elective 
coronary angiography and we found that patients with hyperuricemia are at risk of 
developing CIN (OR=4.71, p=0.019). CIN occurred in 15.1% of the hyperuricemic group and 
2.9% of the normouricemic group (p<0.001). Length of hospital stay (p<0.001) and CIN 
requiring renal replacement therapy (p=0.017) were significantly higher in hyperuricemic 
group. Serum uric acid  7 mg/dl in males and 5.9 mg/dl in females were found the best 
cut-off value for prediction of CIN (Toprak et al., 2006). 
Multivessel coronary involvement, peripheral vascular disease, and renal artery stenosis 
Factors related to accelerated or diffuse atherosclerosis are linked to the development of 
CIN. The treatment of multivessel disease, challenging chronic total occlusions and 
extensively diseased coronary segments, may require high doses of CM for providing an 
optimal image quality, thus enhancing the potential toxic effects on the renal function. If a 
patient has multivessel coronary involvement, the other vessels in the body, such as the 
renal artery, can be involved. In a study of 177 patients who underwent cardiac 
catheterization, subjects were also evaluated for renal artery stenosis. Coronary artery 
disease was detected in 110 patients (62%), and significant renal artery stenosis was detected 
in 19 patients (11%). Using multivariate analysis, it was found that the extent of coronary 
artery disease was an independent predictor of renal artery stenosis (Weber-Mzell et al., 
2002). In a study a total of 5571 patients who underwent PCI were evaluated for CIN risk 
factors, and it was found that multivessel coronary involvement was only a univariate 
predictor of CIN (p=0.003) (Mehran et al., 2004). In two other cohort studies it was found 
that peripheral vascular disease is a risk for CIN in patients who underwent PCI (OR=1.9, 
p<0.0001 and OR=1.71, p=0.001, respectively) (Bartholomew et al., 2004; Rihal et al., 2002).  
In a study a total of 219 non-diabetic patients who underwent coronary angiography we 
have found that multivessel coronary involvement is a risk for CIN (OR=3.24, p=0.038) 
(Toprak et al., 2006). 
Hypovolemia 
Decreased effective circulating volume and reduced renal perfusion potentiate renal 
vasoconstriction after administration of intravascular CM. The toxic effects of CM on the 
renal tubular lumen may be exacerbated in hypovolemia. At present the most convincing 
preventive procedure of CIN is adequate hydration with isotonic saline or sodium 
bicarbonate, and intravenous hydration seems to have better results than does oral 
hydration. Before angiography, the volume status of patients can be assessed through the 
inferior vena cava index, mean atrial pressure, noninvasive pulmonary-capillary wedge 
pressure or bioimpedance spectroscopy (Toprak & Cirit, 2005). 
Renal transplantation 
Patients with renal transplantation may be at a higher risk of CIN due to concomitant use of 
cyclosporine and higher prevalence of diabetes and renal insufficiency. In a study, 33 
patients with a functioning renal allograft who underwent different contrast studies, the 
incidence of CIN was 21.2% (Ahuja et al., 2000). 
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Acute myocardial infarction 
A study by Rihal et al. showed that acute myocardial infarction within 24 h before 
administration of the CM is a risk factor for CIN (OR=1.85, p=0.0006). This study 
demonstrates that CIN is a frequent complication in acute myocardial infarction, even in 
patients with a normal baseline renal function. (Rihal et al., 2002). In a study of 208 acute 
myocardial infarction patients who underwent primary PCI, anterior acute myocardial 
infarction was significantly higher in patients who developed CIN (p=0.0015). However, in 
multivariate analysis, anterior acute myocardial infarction (OR=2.17, p=0.09) was not a risk 
for CIN (Marenzi et al., 2004). In 2082 percutaneous interventions for acute myocardial 
infarction, it was reported a more than seven-fold (3.2% vs 23.3%) increase in 1-year 
mortality in patients who developed CIN (Sadeghi et al., 2003). 
Low hematocrit level 
A baseline hematocrit value of less than 39% for men and less than 36% for women is a risk 
for CIN. The relationship between low hematocrit levels and CIN has been investigated in a 
prospective study of 6773 patients who underwent PCI (Nikolsky et al., 2005). A lower 
baseline hematocrit was an independent predictor of CIN; and each 3% decrease in baseline 
hematocrit resulted in a significant increase in the odds of CIN in patients with and without 
chronic kidney disease (11% and 23%, respectively). Dangas et al. showed that the baseline 
hematocrit level is an independent predictor of CIN in patients with chronic kidney disease 
(OR=0.95, p<0.00001) (Dangas et al., 2005). 
Low serum albumin 
Hypoalbuminemia impairs endothelial function, enhances renal vasoconstriction, impairs 
the synthesis and release of nitric oxide, and decreases antioxidant enzyme activity. In a 
study, low serum albumin (<3.5 g/dl) was identified as a risk factor for CIN in patients 70 
years of age or older who underwent cardiac catheterization (Rich, et al., 1990). Also we 
have found that in 230 patients who underwent coronary angiography with renal 
insufficiency, serum albumin level ≤3.5 g/dl was a risk factor for CIN (OR=5.79, p=0.005) 
(Cirit et al., 2006). 
Hypotension, sepsis, cirrhosis, and pulmonary edema 
A systolic blood pressure of less than 80 mm Hg for at least 1 h that requires inotropic 
support with medications is a risk factor for CIN. A study by Dangas et al showed that 
periprocedural hypotension and pulmonary edema are independent predictors of CIN in 
patients with chronic kidney disease (OR=2.50, p<0.00001 and OR=2.56, p=0.001, 
respectively) (Dangas et al., 2005) Sepsis, through direct damage by bacterial toxins to renal 
tubules and impairment of circulation, has also been reported as a risk factor. Reduction of 
effective intravascular volume caused by liver cirrhosis has been reported as contributing to 
pre-renal reduction in renal perfusion, thus enhancing the ischemic insult of CM (Toprak, 
2007). 
Metabolic syndrome, impaired fasting glucose and hypertriglyceridemia 
In a prospective cohort study of 219 non-diabetic elderly patients with reduced kidney 
function who underwent elective coronary angiography, we reported that metabolic 
syndrome was a risk indicator of CIN (OR=4.26, p=0.026). CIN occurred in 14% of the 
metabolic syndrome group and 3.6% of the non-metabolic syndrome group (relative risk 
3.93, p=0.007). Impaired fasting glucose (OR=4.72, p=0.007), high triglyceride (OR=4.06, 
www.intechopen.com
 
Coronary Angiography and Contrast-Induced Nephropathy 
 
189 
p=0.022); and multi-vessel involvement (OR=3.14, p=0.038) in the metabolic syndrome 
group were predictors of CIN (Toprak et al., 2006). 
2.3.2 Procedure-related risk factors 
Short duration of the two contrast administration and urgent/emergency procedure  
In those who have no risk factors for CIN, angiography should be delayed more than 48 
hours after a previous exposure to intravascular contrast media. In patients with diabetes or 
preexisting renal disease, this time interval should be increased to more than 72 hours. In a 
cohort study, urgent/emergency procedure was found as a predictor of CIN (OR=4, 
p<0.0001) (Bartholomew et al., 2004). The higher risk of developing CIN in patients with 
urgent status was irrespective of baseline renal function.  
Use of intra-aortic balloon pump 
In 208 consecutive acute myocardial infarction patients undergoing percutaneous coronary 
intervention, use of intra-aortic balloon pump was a risk predictor of CIN (OR=15.51, 
p<0.0001) (Marenzi et al., 2004). In a study, it has demonstrated that, intra-aortic balloon 
pump use is an independent predictor of CIN in patients with chronic kidney disease 
(OR=2.27, p=0.004) (Dangas et al., 2005). In another study, it was found that the use of intra-
aortic balloon pump was a risk factor for CIN requiring dialysis after PCI (OR=1.94) 
(Gruberg et al., 2001). In another derivation and validation cohort study, intra-aortic balloon 
pump use was a risk for CIN in patients undergoing coronary intervention (OR=5.1, 
p<0.0001) (Bartholomew et al., 2004). 
Bypass graft intervention and delayed reperfusion  
Procedures with bypass angiography and intervention may be associated with higher 
complexity, longer duration, and limited success, thus indicating an unstable post-
procedural period with impaired cardiac output. Gruberg et al. showed that the risk of CIN 
requiring dialysis after PCI was increased with bypass graft intervention (OR=4.94) 
(Gruberg et al., 2001). In a study of 208 acute myocardial infarction patients undergoing 
primary PCI, the risk of CIN was increased if the time-to-reperfusion is ≥6 h (OR=2.51, 
p=0.04) (Marenzi et al., 2004) 
2.3.3 Contrast medium-related risk factors 
Increased dose of contrast medium 
According to different sources, the relatively safe cutoff point of contrast amount varies 
from 70 ml up to 220ml. However, doses as low as 20 to 30 ml are capable of inducing CIN. 
In a study that patients undergoing coronary angiography, each 100 ml of contrast medium 
administered was associated with a significant increase of 12% in the risk of CIN (OR=1.12, 
p=0.02) (Rihal et al., 2002). Marenzi et al. showed that contrast volume >300 ml is an 
independent risk for CIN (OR=2.80, p=0.02) (Marenzi et al., 2004). In another study patients 
with preexisting renal failure revealed a 10-fold risk of CIN when more than 125 ml of 
contrast media was administered (Taliercio et al., 1986). 
High-osmolar and ionic CM 
In a large study which comparing the non-ionic low-osmolality agent iohexol to the ionic 
high-osmolality agent meglumine/sodium diatrizoate in patients with pre-existing renal 
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dysfunction undergoing angiography, patients with renal insufficiency receiving diatrizoate 
were 3.3 times as likely to develop CIN compared to those receiving iohexol (Rudnick et al., 
1995). NEPHRIC trial is a randomized, prospective study comparing the nonionic iso-
osmolar CM iodixanol with the nonionic low-osmolar CM iohexol in 129 renal impairment 
patients with diabetes undergoing coronary or aorto-femoral angiography. The incidence of 
CIN was 3% in the iodixanol group and 26% in the iohexol group (p=0.002) (Aspelin et al., 
2003). In another randomized study, the renal tolerance of iodixanol and iohexol was 
compared in 124 patients with creatinine >1.7 mg/dl. The incidence of CIN was 3.7% in 
iodixanol group and 10% in iohexol group (p>0.05) (Chalmers et al., 1999). The available 
data do not provide clear evidence that the whole iso-osmolar CM class offers an 
improvement over the low-osmolar CM class. Other studies with iodixanol in renal failure 
patients have shown a higher incidence of CIN than that observed in the NEPHRIC study 
(21% in the RAPPID trial, 30% in the CONTRAST trial) (Baker et al., 2003: Stone et al., 2003). 
In addition to their osmolarity, contrast medias are characterized as ionic versus non-ionic. 
Small clinical trials of low-risk patients undergoing coronary angiography have shown little 
difference in the risk of CIN between the 2 types of CM. However, a randomized trial of 
1196 patients undergoing coronary angiography showed that non-ionic CM reduced the 
incidence of CIN in patients with preexisting renal disease with or without diabetes 
(Rudnick et al., 1995).  In addition, symptomatic or hemodynamic adverse drug events have 
been shown to occur less often with non-ionic, low-osmolality CM compared with ionic, 
high-osmolality CM. In high-risk patients, it is reasonable to don’t use the high-osmolar and 
ionic CM to minimize the risk of CIN. 
Intra-arterial administration of the contrast media 
Intra-arterial contrast administration is a risk for CIN. This effect is thought to be due to the 
fact that the acute intra renal concentration of CM is much higher after intra arterial rather 
than intravenous injection. 
2.3.4 Scoring method to predict high risk patients for CIN 
Mehran et al. developed a simple scoring method that integrates eight baseline clinical 
variables to assess the risk of CIN after percutaneous coronary intervention (PCI). These are 
hypotension (score 5), use of intra-aortic balloon pump (score 5), congestive heart failure 
(score 5), serum creatinine>1.5 mg/dl (score 4), age>75 years (score 4), anemia (score 3), 
diabetes mellitus (score 3), and volume of CM (score 1 per 100 ml). If the total score is 5 or 
less, the risk category is low; if the total score is 16 or higher, the risk category is very high 
(Mehran et al., 2004) 
2.4 Prevention strategies for CIN 
Extracellular volume expansion with intravenous saline or sodium bicarbonate, minimizing 
the dose of CM, using low-osmolar non-ionic CM instead of high osmolar ionic CM, 
stopping the intake of nephrotoxic drugs and avoiding short intervals between procedures 
requiring CM have all been shown to be effective in reducing CIN. Alternatives to ordinary 
CM, such as carbon dioxide or gadolinium chelates, can be used in patients at high risk of 
CIN (Table 2). 
Volume expansion 
Volume expansion is the single most important measure that has been documented to be 
beneficial in preventing CIN. A standardized saline hydration protocol has been proven  
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Clinical evidence advocating 
their use  
Don’t use 
 With conflicting or  
limited evidence 
Extracellular volume 
expansion 
Nonsteroidal anti-
inflammatory drugs, COX-2 
inhibitors,  aminoglycoside, 
cisplatin 
Acetylcystein  
Saline or sodium bicarbonate Loop diuretics  Theophylline  
Low or iso-osmolar contrast Mannitol  Calcium channel blockers  
Minimizing the  dose of 
contrast 
Multiple use of contrast 
within 72 h 
Fenoldopam  
Alternative imaging 
techniques 
Large doses of contrast Captopril  
Monitoring serum creatinine  High-osmolar contrast Ascorbic acid  
Delaying contrast procedures 
until hemodynamic status is 
corrected 
Metformin usage especially in 
patients with renal failure 
Atrial natriuretic peptide 
≥48 h between contrast 
procedures 
 Endothelin antagonist 
  PGE1 
  Hemofiltration 
  Nebivolol 
  Statins 
  B-type natriuretic peptide 
  Pentoxifylline 
Table 2. Prevention strategies for contrast-induced nephropathy in high-risk patients 
effective in reducing the risk of CIN and should be used routinely. The most widely 
accepted protocol is administering isotonic saline at 1 to 1.5 ml/kg/h beginning 6 to 12 
hours prior to the procedure and continuing for up to 12 hours following 
contrastadministration. In a randomized trial, two different hydration regimens were 
compared in 1620 patients undergoing coronary interventions. They showed that the 
incidence of CIN was significantly lower among patients given an isotonic saline solution 
than among those given a hypotonic saline solution (0.7% vs. 2.0% respectively, p=0.04) 
(Mueller et al., 2002). In another trial, a total of 119 patients with serum creatinine exceeding 
1.1 mg/dl were randomized to receive isotonic solution of sodium bicarbonate (n=59) or 
isotonic saline (n=60) at a rate of 3 ml/kg/h for 1 hour before and 1 ml/kg/h for 6 hours 
after contrast administration. CIN developed in only 1 patient (1.7%) compared with 8 
patients (13.6%) in the saline group (p=0.02) (Merten et al., 2004). The authors postulated 
that a reduction in oxidative injury may have conferred protection against CIN. However, 
further studies are required to clarify the role of hydration with sodium bicarbonate in 
preventing CIN. In a prospective study, the effect of combination intravenous and oral 
volume supplementation on the development of CIN was studied in 425 patients 
undergoing percutaneous coronary intervention. Patients were randomly assigned to 
receive hydration with either isotonic or half-isotonic. In addition patients were encouraged 
to drink plenty of fluids (at least 1500 ml). They found that applying the combination of 
intravenous and oral volume supplementation results in a very low incidence of CIN (1.4%) 
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(Mueller et al., 2005). Most studies have found that hydration alone is better than hydration 
combined with a diuretic. In a study, 78 patients with serum creatinine >1.6 mg/dl were 
randomized to three groups: hydration alone, hydration with mannitol and hydration with 
furosemide. Half-isotonic saline was used for hydration. CIN occurred in 11%, 28% and 40% 
of patients in the three groups, respectively (p=0.02), thus showing that forced diuresis is of 
no benefit in preventing CIN. In a meta-analysis it was found that the administration of 
sodium bicarbonate is superior to the administration of saline alone in the prevention of 
CIN (Solomon et al., 1994). However, further controlled clinical trials are needed due to 
significant study heterogeneity and publication bias. The effectiveness of sodium 
bicarbonate treatment to prevent CIN in high-risk patients remains uncertain. 
N-acetylcysteine 
It had been postulated that antioxidant N-acetylcysteine (NAC) might scavenge oxygen free 
radicals, thus attenuate the cytotoxic effects of CM. NAC may also have direct vasodilating 
effects on the kidneys through an increase in the biologic effects of nitric oxide. Tepel et al. 
were evaluated the effects of NAC (600 mg orally twice daily), at first time, in 83 patients 
undergoing computed tomography. Two percent of the patients in the NAC group had CIN 
versus 21% in the placebo group (p=0.01) (Tepel et al., 2000). Since then, a number of trials 
have been published. Results from these trials have been inconsistent. In a randomized, 
placebo-controlled study it was found that NAC is protective against CIN Fifty-four patients 
were randomized to receive either 600 mg of NAC twice daily for 4 doses or placebo. The 
incidence of CIN was 8% in the NAC group versus 45% in the placebo group (p=0.005) 
(Diaz-Sandoval et al., 2002). In addition to oral administration, intravenous administration 
of NAC to protect against CIN has also been evaluated. In a study, Baker et al. randomly 
assigned 80 patients to receive either NAC infusion (n=41) versus saline infusion (n=39). 
CIN developed in only 2 (5%) of patients in the NAC group compared with 8 (21%) in the 
saline group (p=0.04) (Baker et al., 2003). The authors concluded that NAC infusion protects 
against CIN. In a meta-analysis, evaluating more than 800 patients at high risk of 
developing CIN also documented a positive impact of NAC prophylaxis on CIN (Birck et 
al., 2003). In another meta-analysis, nine randomized controlled trials were included and the 
difference in mean change in creatinine between the NAC treated group and controls was -
0.27 mg/dl. The relative risk of developing CIN was 0.43 in subjects randomized to NAC. 
They suggest that NAC helps prevent declining renal function and CIN (Liu et al., 2005). In 
contrast to these reports, some studies failed to find a significant effect of NAC on the 
occurrence of CINA total of 183 patients with preexisting renal insufficiency undergoing 
contrast study were randomly assigned to receive NAC at a dose of 600 mg twice daily on 
the day before and the day of the contrast study plus saline infusion or saline alone. The 
incidence of CIN was 6.5% in the NAC group versus 11% in the control group (p=0.22) 
(Briguori et al., 2002).  In a multi centric double blind clinical trial 156 patients undergoing 
coronary angiography or percutaneous coronary intervention with creatinine clearance <50 
ml/min were randomly assigned to receive N-acetylcysteine 600 mg orally twice daily for 
two days or placebo. Sixteen patients developed CIN. Eight of 77 patients (10.4%) in the 
NAC group and eight of 79 patients (10.1%) in the placebo group (p=1.00). No difference 
was observed in the change in endogenous creatinine clearance, p=0.28). They concluded 
that oral NAC did not prevent CIN in patients at low to moderate risk undergoing cardiac 
catheterisation with ionic low osmolality CM (Gomes et al., 2005). In another study, 50 
patients undergoing elective diagnostic coronary angiography with serum creatinine values 
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above 1.3 mg/dl were included and CIN was detected in 3 of 25 patients (12%) in the NAC 
group and 2 of 25 patients (8%) in the control group (p>0.05). It was detected that in patients 
planned to undergo elective diagnostic coronary angiography with renal dysfunction, oral 
NAC and hydration before the procedure was not more effective than hydration alone in the 
prevention of CIN (Gulel et al., 2005). A direct renoprotective effect of NAC remains 
questionable. To date, only a few trials described the effects of NAC not only on serum 
creatinine but also on clinical end points. The serum creatinine can be decrease in 
administration of NAC without renoprotective effect.  In a prospective study, NAC was 
given at a dose of 600 mg every 12 h for a total of four doses to the volunteers with a normal 
renal function who did not receive contrast agent. There was a significant decrease of the 
mean serum creatinine (p<0.05) and a significant increase of the GFR (p<0.02), whereas the 
cystatin C concentration did not change significantly (Hoffmann et al., 2004). In patients 
undergoing emergency diagnostic procedures, in whom a full hydration protocol is not 
possible, an abbreviated hydration regimen plus oral or intravenous administration of NAC 
can be recommended. NAC may be of benefit mostly in high-risk patients. If NAC is to be 
used as a preventative measure, it should be given at a dose of 600 mg orally twice daily on 
the day before and day of the procedure. 
Ascorbic acid 
Prophylactic oral administration of ascorbic acid may protect against CIN. In a randomized, 
placebo-controlled trial in 231 patients with serum creatinine concentration ≥1.2 mg/dl who 
undergoing coronary angiography showed that the use of ascorbic acid was associated with 
a significant reduction in the rate of CIN. CIN occurred in 11 of the 118 patients (9%) in the 
ascorbic acid group and in 23 of the 113 patients (20%) in the placebo group (OR=0.38; 
p=0.02) (Spargias et al., 2004). Further prospective studies are needed to validate these 
preliminary results. 
Fenoldopam 
Fenoldopam mesylate is a selective dopamine-1 receptor agonist that produces systemic, 
peripheral and renal arterial vasodilatation. Several investigators have reported a positive 
impact of fenoldopam against CIN in small studies. In a placebo-controlled, double-blind, 
multicenter trial, 315 patients with creatinine clearance of less than 60 ml/min were 
randomized to receive fenoldopam infusion [0.05 µg/kg/min titrated to 0.1 µg/kg/min 
(n=157)] or matching placebo (n=158). CIN occurred in 33.6% of patients in the 
fenoldopam group compared with 30.1% of patients in the placebo group (p=0.61) (Stone 
et al., 2003). The authors concluded that fenoldopam did not protect against CIN. In 2 
other large studies comparing fenoldopam with NAC treatment with fenoldopam either 
had a similar, non significant effect as that of NAC or was inferior to it (Allaqaband et al., 
2002; Briguori et al., 2004). Therefore, the routine use of fenoldopam cannot be 
recommended at the present time. 
Adenosine antagonists  
CM stimulate the intrarenal secretion of adenosine, which binds to the renal adenosine 
receptor and acts as a potent vasoconstrictor, reducing renal blood flow and increasing the 
generation of oxygen free radicals as it is metabolized to xanthine and hypoxanthine. 
Theophylline and aminophylline, adenosine antagonists, have also been studied in the 
prevention of CIN in a number of trials. Studies with these agents have used varying doses 
and dosage forms and yielded conflicting results (Erley et al., 1999; Kapoor et al., 2001). 
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Based on the conflicting information found in clinical studies, adenosine antagonists should 
not be routinely used in patients as a preventative measure at this time. 
Calcium channel blockers 
The calcium channel antagonists verapamil and diltiazem have been found to attenuate the 
renal vasoconstrictor response after exposure to CM. However, when the efficacy of the 
felodipine, nitrendipine and nifedipine was evaluated, results were inconsistent. Two small 
studies performed the use of sublingual nifedipine given prior to contrast administration. 
Patients (n=20) who received sublingual nifedipine did not have a significant increase in 
serum creatinine, while those in the placebo group did (Rodicio et al., 1990).  In another 
study, patients (n=30) who received nifedipine had an increase in renal plasma flow 
following administration of contrast, while patients in the placebo group had a decrease in 
renal flow (Russo et al., 1990). One other study showed that nitrendipine use cause a 
significant reduction in the GFR in the placebo group compared to little or no change in GFR 
in the nitrendipine group (Neumayer et al., 1989). In another study, 27 patients with normal 
to moderately reduced renal function underwent femoral angiography randomized to 
receive either oral felodipine or placebo. Patients in the felodipine group had a significant 
increase in serum creatinine from baseline, while patients in the placebo group did not 
demonstrate a similar increase (Spangberg-Viklund et al., 1996). More large-scale trials are 
needed before calcium channel blockers can be routinely recommended in patients prior to 
contrast administration. 
Prostaglandin E1 
PGE1 has vasodilatory effects that may be beneficial in preventing CIN. In one study, 130 
patients were randomly assigned to receive either placebo or one of three doses of PGE1. The 
increase in serum creatinine level was smaller in all of the three PGE1 groups than in the 
placebo group, but the difference was significant only in the medium-dose (20 ng/kg/min) 
of PGE1 group (Koch et al., 2000). More studies need to be done to better understand the role 
of prostaglandin E1, but results from this pilot study appear promising. 
Atrial natriuretic peptide (ANP) 
ANP may prevent CIN by increasing renal blood flow. In a study, ANP was included in one 
of the four arms. In which dopamine, mannitol, and ANP caused an increase in CIN in 
diabetic patients as compared to saline alone (Weisberg et al., 1994). In another trial patients 
were randomized to one of four treatment arms: fluid alone or one of three doses of ANP. 
Results showed no statistically significant differences in the incidence of CIN between any of 
the four treatment arms (Kurnik et al., 1998) Based on these results and the limited clinical 
data, ANP cannot be advocated in the prevention of CIN.  
Endothelin antagonists 
Endothelin-1 is a potent endogenous vasoconstrictor, is thought to play a role in the 
development of CIN. Endothelin-1 has two primary receptors. In animal studies, endothelin-
A antagonists were shown to reduce the incidence of CIN (Liss et al., 2003). However, in a 
randomized study of 158 patients, the use of a mixed endothelin-A and B antagonist was 
associated with a significantly higher incidence of CIN than was placebo (56% vs. 29%, 
p=0.002) (Wang et al., 2000). Endothelin antagonists currently have no role in prevention of 
CIN. 
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Low-dose of dopamine 
At low doses (1-3 mcg/kg/min), dopamine activates two types of dopamine (DA) receptors, 
DA-1 and DA-2. Activation of the DA-1 receptor results in an increase in natriuresis and 
renal blood flow. Since dopamine, at low doses, is believed to be more selective for the DA-1 
receptors, it has been investigated in the prevention of CIN. Kapoor et al. randomized 40 
patients with diabetes scheduled to undergo a coronary angiography to either dopamine or 
placebo control. None of the patients in the dopamine group developed CIN compared to 
50% of patients receiving placebo (Kapoor et al., 2002). In another prospective, randomized 
trial, Hans et al. evaluated 55 patients (40% had diabetes) with chronic renal insufficiency. 
Patients were randomized to receive dopamine or an equal volume of saline. The group 
receiving dopamine had a significantly lower incidence of CIN as compared to the control 
group (Hans et al., 1998). In contrast to the trials showing a potential benefit of dopamine, 
other studies have failed to demonstrate this benefit. Abizaid et al. performed a randomized, 
prospective study involving patients with renal insufficiency who underwent coronary 
angioplasty. Patients were randomized to continue with the saline, receive aminophylline in 
addition to the saline, or receive dopamine plus saline. In the dopamine plus saline group, 
50% of patients developed CIN, while only 30% of the patients in the saline-alone group 
developed CIN. This difference did not reach statistical significance, but it appeared that use 
of dopamine might worsen outcomes (Abizaid et al., 1999). Low-dose dopamine use cannot 
be supported at this time.  
Statins 
Whether additional benefits can be achieved with the use of statin in decreasing the risk of 
CIN remains undetermined. In a recent meta analysis of randomised controlled trials 
comparing statin pretreatment with non-statin pretreatment for the prevention of CIN, it 
was found that, the incidence of CIN was not significantly lower in statin pretreatment 
group as compared with control group (RR=0.76, p=0.30) (Zhang et al., 2011). The current 
cumulative evidence suggests that statin pretreatment may neither prevent CIN nor reduce 
the need for renal replacement therapy. 
Hemofiltration and hemodialysis 
Currently available data do not support use of prophylactic hemodialysis for prevention of 
CIN. In a trial of 113 patients, reported that CIN occurred in 24% of the hemodialysis group 
as compared with 16% of non-hemodialysis group (Vogt et al., 2001). Clinically relevant 
events also were not different in two groups. Only continuous venovenous hemofiltration 
has been shown to protect against CIN. In a study, 114 patients with chronic renal failure 
undergoing percutaneous coronary intervention were divided in two groups: 56 patients 
received normal saline and 58 patients underwent hemofiltration at a rate of 1000 ml/h 
(Marenzi et al., 2003).  Hemofiltration seems to have a protective effect, including significant 
reduction in in-hospital and 1-year mortality compared with routine hydration. The 
mechanisms of this benefit are not clear. Further studies are needed to confirm the results of 
this trial.  
New types of contrast medias 
Gadolinium-enhanced magnetic resonance coronary angiography is a non-invasive method 
for evaluation of coronary arteries. It has been suggested that gadolinum-based CM could 
be used in stead of iodinated CM for radiological examinations in patients with significant 
www.intechopen.com
 
Advances in the Diagnosis of Coronary Atherosclerosis 
 
196 
renal impairment. However, its use has been questioned on the basis of reports of 
nephrotoxicity and its association with nephrogenic systemic fibrosis, a rare and serious 
syndrome that involves fibrosis of skin, joints, eyes, and internal organs. In a study by 
Hoffmann et al. the effect of gadopentetate dimeglumine (iodine-based CM) was studied in 
181 patients with normal renal function and the effect of gadolinium was studied in 198 
patients with pre-excisting renal failure. There was no statistically significant change in 
serum creatinine concentration after gadopentetate dimeglumine. In contrary, serum 
creatinine levels decreased significantly after the administration of gadolinium (p<0.01) 
(Hoffmann et al., 2005).  In a retrospective study, the safety of gadolinium was evaluated in 
91 patients with stage 3 and 4 renal failure who underwent angiographic MRI procedures. 
Eleven of 91 patients developed CIN (12.1%) (Ergun et al., 2006). In another randomized 
study gadobutrol, a gadolinium-based CM, was compared with standard iohexol, an 
iodinated CM, in 21 patients with renal dysfunction. The incidence of CIN was 50% in 
gadobutrol group and 45% in iohexol group (p=0.70). In this study, gadolinium showed no 
benefit over iohexol in patients with severely impaired renal function (Erley et al., 2004). 
More studies need to be done to better understand the role of gadolinum on CIN. 
Ultrasound contrast agents are micro-bubbles which produce acoustic enhancement. They 
are pharmacologically almost inert and safe. 
3. Conclusion 
The development of CIN is associated with adverse outcomes including prolonged 
hospitalization, the potential need for renal replacement therapy, and most important, 
increased mortality. The treatment of established CIN is limited to supportive measures and 
dialysis. For this reason, screening for high-risk patients before CM including cardiac 
procedures and taking the appropriate prophylactic regimens is important in reducing CIN. 
Pre-existing renal dysfunction, especially when secondary to diabetic nephropathy, is the 
most important risk factor. Extra cellular volume expansion and use of low osmolar CM are 
the two most effective measures to prevent CIN. Acetylcysteine may use in high-risk 
patients, but this finding has not been uniform or always demonstrated by currently 
available trials.  
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complications have been presented in this book. Other important issue is radiation exposure of patients and
staff during coronary angiography and scintigraphy. Radiation dose reduction techniques, general radiation
protection principles have been discussed in related chapters.
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